当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
PANZYGA, Immune Globulin Intravenous (Human)-ifas
申请企业
Octapharma Pharmazeutika Produktionsges.m.b.H.
药品名称
PANZYGA, Immune Globulin Intravenous (Human)-ifas
承诺描述
Deferred pediatric study studies under PREA for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in pediatric patients ages 2 to 17 years of age.
承诺状态描述
The study has not been initiated but does not meet the criterion for delayed.